| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000004466 |
| Receipt No. | R000005324 |
| Official scientific title of the study | A phase II trial of TS-1/CDDP as neoadjuvant chemotherapy against resectable gastric cancer. |
| Date of disclosure of the study information | 2010/10/28 |
| Last modified on | 2017/05/01 (Ver. 7) |
| Basic information | ||
| Official scientific title of the study | A phase II trial of TS-1/CDDP as neoadjuvant chemotherapy against resectable gastric cancer. | |
| Title of the study (Brief title) | A phase II trial of TS-1/CDDP as neoadjuvant chemotherapy against resectable gastric cancer. | |
| Region |
|
|
| Condition | |||
| Condition | Gastric cancer | ||
| Classification by specialty |
|
||
| Classification by malignancy | Malignancy | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | The aim is to evaluate the clinical pathology effects of TS-1 plus cisplatin as a neoadjuvant chemotherapy against resectable gastric cancer. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The effect of the tumor reduction of providing by the chemotherapy effect judgment standard is used.
The doctor in charge judges the effect of the tumor reduction based on RECIST(http://www.recist.com/recist-in-practice/22.html) version 1.1. |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Cluster |
| Blinding | Open -no one is blinded |
| Control | No treatment |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | TS-1: Day1-21, p.o. and CDDP: Day8.
1 course takes 35 days. 1 course |
|
| Interventions/Control_2 | TS-1: Day1-21, p.o. and CDDP: Day8.
1 course takes 35 days. 2 courses |
|
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1.Primary gastric adenocarcinoma
2.The pathological material of the gastric carcinoma before chemotherapy 3.M (-),H (-),c-StageIII and IV in the staging classification 4.Adjustment of Neoadjuvant chemotherapy with TS-1+CDDP 5.Measurable lesions according to RECIST guidelines 6.No history of pretreatment (radiotherapy, chemotherapy,etc.) except surgery 7.PS(ECOG) is 0-2 8.Adequate organ function WBC>=4000/mm3 Neutrophil count>=2,000/mm3 Platelet count>=100,000/mm3 Hemoglobin>=8.0 g/dL 9.Liver function tests AST (GOT) and ALT (GPT) <=100IU/L Total bilirubin<=2.0 mg/dL 10.Renal function test CCr(e-GFR)>=60ml/min Serum creatinine<=1.50 mg/dL 11.Age 20 to 80 years old 12.With written informed consent |
|||
| Key exclusion criteria | 1.Metachronous or synchronous multiple cancer
2.Pregnant or in lactation. 3.Patient who is judged to be inappropriate as subject to this study by the principal investigator or the doctors in charge. |
|||
| Target sample size | 110 | |||
| Research contact person | |
| Name of lead principal investigator | Hideaki Shimada |
| Organization | Toho University School of Medicine |
| Division name | Division of general and Gastroenterological Surgery,Department of Surgery(Omori) |
| Address | 6-11-1 Omori-Nishi,Ota-ku,Tokyo 143-8541,Japan |
| TEL | 03-3762-4151 |
| hideaki.shimada@med.toho-u.ac.jp | |
| Public contact | |
| Name of contact person | Hideaki Shimada |
| Organization | Toho University School of Medicine |
| Division name | Division of general and Gastroenterological Surgery,Department of Surgery(Omori) |
| Address | 6-11-1 Omori-Nishi,Ota-ku,Tokyo 143-8541,Japan |
| TEL | 03-3762-4151 |
| Homepage URL | |
| hideaki.shimada@med.toho-u.ac.jp | |
| Sponsor | |
| Institute | Toho University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005324 |